Assyro AI

Orange Book product · Brand (NDA)

TIVICAY

DOLUTEGRAVIR SODIUM

Brand (NDA)NDA 204790DISCN VIIV HLTHCARE

At a glance

Jun 09, 2016

Approved

Brand (NDA)

Application

Not listed

TE code

4

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Jun 09, 2016

    10 yr 2 mo ago

  2. Today

  3. Patent 8129385 expires

    Listed drug substance patent expiration.

    Oct 05, 2027

    in 1 yr 4 mo

  4. Patent 8129385*PED expires

    Listed listed patent expiration.

    Apr 05, 2028

    in 1 yr 10 mo

  5. Patent 9242986 expires

    Listed drug substance patent expiration.

    Dec 08, 2029

    in 3 yr 6 mo

  6. Patent 9242986*PED expires

    Listed listed patent expiration.

    Jun 08, 2030

    in 4 yr

Pharmaceutical detail

Active ingredient

DOLUTEGRAVIR SODIUM

Strength

EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 204790

Product number

002

Marketing status

DISCN

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (4)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8129385Oct 05, 2027in 1 yr 4 mo
SubstanceProduct
8129385*PEDApr 05, 2028in 1 yr 10 mo
9242986Dec 08, 2029in 3 yr 6 mo
SubstanceProduct
9242986*PEDJun 08, 2030in 4 yr
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.